Document is current
Any future updates will be listed below
-
Authors
Xu, Binghe
Li, Huiping
Zhang, Qingyuan
Sun, Wan
Yu, Yanke https://orcid.org/0000-0002-3276-0130
Li, Wei
Wang, Shusen
Liao, Ning
Shen, Peng
Liu, Yuan
Huang, Yaling
Linn, Carlos
Zhao, Huadong
Jiang, John
Wang, Diane
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02499146 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women
https://doi.org/10.1007/s00280-021-04263-9
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 11 December 2020
Accepted: 16 March 2021
First Online: 9 April 2021
Declarations
:
: Binghe Xu has served on speakers’ bureaus for AstraZeneca, Pfizer, Roche, and Eisai; and his institute received research funding for this study from Pfizer. Huiping Li, Qingyuan Zhang, Wei Li, Shusen Wang, Ning Liao, and Peng Shen have no conflicts of interest to report. Yanke Yu, Yuan Liu, Carlos Linn, Huadong Zhao, and Diane Wang are employees of and stockholders in Pfizer Inc. Yaling Huang, Wan Sun, and John Jiang are former employees of Pfizer Inc.
: The study protocol was reviewed and approved by the Independent Ethics Committee at each of the participating study sites. The study was conducted in compliance with the principles of the Declaration of Helsinki and with all International Council for Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent.
